Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069925 | 0.94 | TLR4 (0.42) | TLR4DDB1CRBNCA1CA2 | |
| SCHEMBL361599 | 0.79 | DDB1 (0.48) | IGF1RALOX15DDB1CRBNTP53 | |
| SCHEMBL512106 | 0.76 | SRD5A1 (0.41) | ALOX15 | |
| SCHEMBL361341 | 0.76 | LMNA (0.43) | ALOX15L3MBTL1 | |
| SCHEMBL4917555 | 0.76 | LIG1 (0.40) | ALOX15 | |
| SCHEMBL6435720 | 0.76 | CYP19A1 (0.42) | DDB1CRBNCA1CA2L3MBTL1 | |
| SCHEMBL15874652 | 0.73 | SLC18A3 (0.51) | TLR4IGF1RALOX15DDB1CRBN | |
| SCHEMBL9328018 | 0.73 | SLC18A3 (0.51) | TLR4IGF1RALOX15DDB1CRBN | |
| SCHEMBL190786 | 0.73 | SLC18A3 (0.51) | TLR4IGF1RALOX15DDB1CRBN | |
| SCHEMBL23468094 | 0.73 | TRIM24 (0.36) | TLR4TP53L3MBTL1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026510-B2 | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | Dompé S.p.A. (IT) | 2006-04-11 | — | — | US | claimed |
| CN-1625411-A | Combination of a NSAID and a PDE-4 inhibitor | ALTANA PHARMA AG (DE) | 2005-06-08 | — | — | CN | claimed |
| US-20040266870-A1 | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-12-30 | — | — | US | claimed |
| EP-1430020-A1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-06-23 | — | — | EP | claimed |
| WO-2003029187-A1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-04-10 | — | — | WO | claimed |
| US-7026510-B2 | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | Dompé S.p.A. (IT) | 2006-04-11 | — | — | US | disclosed |
| US-20040266870-A1 | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-12-30 | — | — | US | disclosed |
| EP-1430020-A1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003029187-A1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266870-A1 | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | C3AR1, IL5, AP1G1 | TLR4 1618/4885IGF1R 2830/4885ALOX15 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.